Skip to main content

Table 2 Resume of CNZ/FNZ-associated movement disorders

From: Cinnarizine- and flunarizine-associated movement disorder: a literature review

Movement disorderPKNDKNAKTDTNMCLOthersGeneral data
Cases (%)1251 (65.15)23 (1.19)11 (0.57)16 (0.83)5 (0.26)614 (31.97)1920
Continent (%)Asian332 (26.53)0 (0)1 (9.09)2 (12.5)1 (20)498 (81.10)834
European575 (45.96)4 (17.39)4 (36.36)5 (31.25)0 (0)75 (12.21)663
North America1 (0.07)0 (0)0 (0)0 (0)4 (80)3 (0.48)8
South America343 (27.41)19 (82.60)6 (54.54)9 (56.25)0 (0)38 (6.18)415
Sex (%)Female429 (34.29)19 (82.60)5 (45.45)10 (62.5)3 (60)NA466
Male161 (12.86)4 (17.40)2 (18.18)6 (37.5)2 (40)175
Unknown661 (52.83)0 (0)4 (36.36)0 (0)0 (0)1294
Age (years)Range25–9359–8449–7410.5–702.5–702.5–93 (Md, 71.1)
Mean75.6367.8764.7153.5953.174.49 (SD, 7.88)
Number of reports with the drug (mean dose in mg)CNZ347 (150.12)3 (175)1 (75)2 (32.5)3 (NA)356 (Mn, 148.19; SD, 42.51; Md, 154.4; Rg, 25–225)
FNZ570 (11.19)10 (10.16)6 (20)3 (8.33)1 (NA)590 (Mn, 11.22; SD, 5.39; Md, 10; Rg, 5–60)
FNZ +CNZ18 (12.08 + 133.06)1 (10 + 25)03 (13.73 + 124.03)1 (NA)23 (Mn, 12.19 + 126.91; SD, 2.91 + 39.80; Rg, 8.75–20 + 25–154.4)
Unknown CNZ/FNZ31691480951
MD onsetRange2 days–5 years3 months–5 years1 day–5 years1 day–6 years1 week–20 years1 day–20 years (Md, 1.25)
Mean (years)1.742.212.542.467.75Mn, 1.83 (SD, 1.35)
MD recoveryRange7 days–10 months2 weeks–5 months1 day–8 months1.5 days–1 year3 days–5 years1 day–5 years (Md, 3 months)
Mean (months)3.612.453.294.4120.363.71 (SD, 1.26)
Follow-up, % CR (number of reports)94.85% (406/428)66.66% (10/15)100% (7/7)91.66% (11/12)75% (3/4)93.77% (437/466)
  1. Abbreviations: AKT akathisia, CR complete recovery, DKN dyskinesia, DTN dystonia, MCL myoclonus, MD movement disorder, Md median, Mn mean, NA not available/not applicable, PKN parkinsonism, SD standard deviation, Rg range (minimum–maximum). In the “Others” subgroup are cases not specified about the movement disorder such as extrapyramidal symptoms, tremor, bradykinesia, and myokymia